Cabozantinib Impurities

Cabazitaxel, a second-generation semisynthetic microtubule inhibitor, stabilizes microtubules and causes the death of cancer cells.

Show
per page

Cabozantinib Related Compound

Cabozantinib has a distinct immunomodulatory profile, has shown clinical success in mRCC and mUC as a monotherapy, and maybe a good companion for checkpoint inhibitor treatment.

References

  • El-Khoueiry, Anthony B., et al. “Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma.” Cancer Treatment Reviews, vol. 98, Elsevier BV, July 2021, pp. 102221–21, https://doi.org/10.1016/j.ctrv.2021.102221. Accessed 9 Sept. 2023.
  • “Cabozantinib: Uses, Interactions, Mechanism of Action | DrugBank Online.” Drugbank.com, DrugBank, 2016, go.drugbank.com/drugs/DB08875. Accessed 9 Sept. 2023.
  • “Jevtana (Cabazitaxel Injection): Uses, Dosage, Side Effects, Interactions, Warning.” RxList, RxList, 25 July 2023, www.rxlist.com/jevtana-drug.htm. Accessed 9 Sept. 2023.

FAQ

What type of therapy is cabozantinib?

It is a member of two categories of medicines used in targeted treatment. It is recognized as an angiogenesis inhibitor as well as a growth inhibitor for cancer. Medullary thyroid cancer, kidney cancer, and liver cancer are all treated with cabozantinib.

What is the mode of action of cabozantinib?

Cabozantinib suppresses metastasis, angiogenesis, and oncogenesis by inhibiting receptor tyrosine kinases. Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2, and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.

Is cabozantinib an Immunosuppressant?

Preclinical studies suggest cabozantinib may encourage an immune-permissive tumor microenvironment (TME) and boost responsiveness to ICIs. Cabozantinib targets are also implicated in immunosuppression. Immunosuppressive cells become more active and numerous in the TME as a result of VEGF generated by tumor cells.